H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $40 from $36 and keeps a Buy rating on the shares. The firm believes the Merus (MRUS) acquisition bolsters Genmab’s late-stage pipeline. Petosemtamab’s market opportunity in head and neck cancer alone could exceed $3B annually, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab A/S Updates Articles of Association to Enhance Growth Strategy
- Genmab’s Strategic Acquisitions and Promising Pipeline Drive Buy Rating
- Genmab’s Strategic Acquisition of MRUS: A Long-Term Positive Move Enhancing Pipeline and Growth Potential
- Genmab price target raised to $34 from $32 at Leerink
- Video: Merus jumps after deal to be bought, MoonLake sinks after trial data